Entera Bio financials
$2.690.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $42.0K | $82.0K | $42.0K | $57.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $9.0K | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 15.8% | — | — | — |
| Operating income | -$4.6M | -$3.5M | -$3.0M | -$3.3M | -$2.7M | -$2.6M | -$2.3M | -$3.0M | -$2.2M | -$2.1M | -$2.0M | -$2.4M |
| Net income | -$7.3M | -$3.5M | -$3.0M | -$3.2M | -$2.7M | -$2.6M | -$2.4M | -$3.0M | -$2.1M | -$2.0M | -$2.0M | -$2.4M |
| Net margin | — | — | — | — | — | −6111.9% | −2875.6% | −7192.9% | −3763.2% | — | — | — |
| Diluted EPS | $-0.14 | $-0.07 | $-0.06 | $-0.07 | $-0.06 | $-0.06 | $-0.06 | $-0.08 | $-0.06 | $-0.05 | $-0.07 | $-0.08 |
| EBITDA | -$4.6M | -$3.5M | -$3.0M | -$3.2M | -$2.7M | -$2.6M | -$2.3M | -$3.0M | -$2.2M | -$2.0M | -$2.0M | -$2.4M |
| Operating cash flow | -$3.5M | -$3.1M | -$1.8M | -$2.5M | -$1.6M | -$1.4M | -$1.5M | -$2.2M | -$1.3M | -$1.9M | -$2.6M | -$1.5M |
| Free cash flow | -$3.5M | -$3.1M | -$1.9M | -$2.5M | -$1.7M | -$1.4M | -$1.5M | -$2.2M | -$1.3M | -$1.9M | -$2.6M | -$1.5M |
| Diluted shares | 50.5M | 47.8M | 47.5M | 47.1M | 46.8M | 43.4M | 39.1M | 37.6M | 37.1M | 36.7M | 29.6M | 28.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.3M | $4.1M | $7.1M | $8.6M | $10.9M | $12.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $284.0K | $567.0K | $393.0K | $527.0K | $524.0K | $515.0K |
| Total assets | $19.5M | $13.1M | $16.0M | $17.4M | $19.7M | $21.6M |
| Total liabilities | $12.2M | $2.4M | $2.9M | $2.2M | $2.4M | $2.2M |
| Shareholders' equity | $7.3M | $10.7M | $13.1M | $15.2M | $17.3M | $19.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology